Sort   by:  
 Page size 
UnknownExamining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study.

Introduction

The applicability of neoadjuvant treatment (NAT) for resectable pancreatic ductal adenocarcinoma (PDAC) has arisen, however, high-level evidence is lacking. This study aimed to explore patient subgroups with high-risk resectable PDAC for selecting candidates who may benefit from...
S-EPMC11093487 | biostudies-literature
UnknownClinical outcomes of preservation versus resection of portal/superior mesenteric vein during pancreaticoduodenectomy in pancreatic cancer patients who respond to neoadjuvant treatment: a retrospective cohort study.

Background

R0 rates have increased as neoadjuvant treatment (NAT) has become the primary treatment for pancreatic ductal adenocarcinoma (PDAC) with venous involvement, suggesting a decrease in venous tumor infiltration. The aim of this study was to investigate the clinical outcomes of preser...
S-EPMC11573088 | biostudies-literature
UnknownComparisons of short-term outcomes of anastomotic methods of duct-to-mucosa pancreaticojejunostomy: out-layer continuous suture versus modified Blumgart method.

Purpose

Postoperative pancreatic fistula (POPF) is the most troublesome complication after pancreaticojejunostomy (PJ). This study aimed to compare the short-term outcomes of 2 different methods of duct-to-mucosa PJ; out-layer continuous suture anastomosis (OCA) and the modified Blumgart met...
S-EPMC9763782 | biostudies-literature
UnknownThe Small-Molecule Wnt Inhibitor ICG-001 Efficiently Inhibits Colorectal Cancer Stemness and Metastasis by Suppressing MEIS1 Expression.
Recurrence and metastasis remain major obstacles in colorectal cancer (CRC) treatment. Recent studies suggest that a small subpopulation of cells with a self-renewal ability, called cancer stem-like cells (CSCs), promotes recurrence and metastasis in CRC. Unfortunately, no CSC inhibitor has been dem...
S-EPMC8704261 | biostudies-literature
UnknownSLC6A14-mediated glutamine promotes SYTL4-CXCL8 axis activation to drive gemcitabine resistance and immune evasion in pancreatic cancer.
Chemoresistance remains a major challenge in pancreatic ductal adenocarcinoma (PDAC). Glutamine sustains drug resistance and shapes the immunosuppressive tumor microenvironment; however, the underlying mechanisms remain unclear. Identifying key regulators that drive both gemcitabine resistance and i...
S-EPMC12800172 | biostudies-literature
UnknownRole of Adjuvant Chemotherapy in Distal Cholangiocarcinoma.

Background

Recent studies addressing the role of adjuvant chemotherapy (AC) in cholangiocarcinoma (CCA) have been published; however, there are challenges in generalizing the findings due to different prognostic characteristics depending on tumor location and resectability. Therefore, this s...
S-EPMC12380034 | biostudies-literature
UnknownEfficacy of Neoadjuvant Radiotherapy After Chemotherapy and the Optimal Interval from Radiotherapy to Surgery for Borderline Resectable and Resectable Pancreatic Cancer.

Background

Benefits of neoadjuvant treatment for pancreatic cancer with major vessel invasion has been demonstrated through randomized controlled trials; however, the optimal neoadjuvant treatment strategy remains controversial, especially for radiotherapy. Therefore, we aimed to evaluate th...
S-EPMC11882644 | biostudies-literature
ProteomicsDIA-based Proteomic analysis of human islets with treatment of a PERK inhibitor
Partial downregulation of pancreatic endoplasmic reticulum kinase (PERK) activity recovered insulin content in human islets exposed to glucolipotoxicity (GLT), resulting in improved insulin secretion and glucose-lowering effects in a mouse model of type 2 diabetes. We conducted this study to elucida...
ORGANISM(S): Homo sapiens (Human) 
2026-06-29 | PXD074587 | Pride
Human Islets Dia Perk inhibitor 
ProteomicsProteomic analysis on human islet with treatment of a PERK inhibitor
Partial downregulation of pancreatic endoplasmic reticulum kinase (PERK) activity recovered insulin content in human islets exposed to glucolipotoxicity (GLT), resulting in improved insulin secretion and glucose-lowering effects in a mouse model of type 2 diabetes. We conducted this study to elucida...
ORGANISM(S): Homo sapiens (Human) 
2026-06-29 | PXD066613 | Pride
Tmt Perk inhibitor Islet 
UnknownProspective Comparison of [<sup>18</sup>F]FDG and [<sup>18</sup>F]AIF-FAPI-74 PET/CT in the Evaluation of Potentially Resectable Pancreatic Ductal Adenocarcinoma.

Purpose

Accurate clinical staging of potentially resectable pancreatic ductal adenocarcinoma (PDAC) is critical for establishing optimal treatment strategies. While the efficacy of fluorine-18-fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) ...
S-EPMC11634952 | biostudies-literature
Sort   by:  
 Page size